sample_id stringlengths 11 11 | clinical_text stringlengths 18 347 | category stringclasses 5
values | subcategory stringclasses 20
values | difficulty stringclasses 4
values | drug_mentions listlengths 1 14 | regimen_mentions listlengths 0 2 | num_drugs int64 1 8 | note_type stringclasses 10
values |
|---|---|---|---|---|---|---|---|---|
ONCORX-0001 | The patient was started on Abemaciclib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Abemaciclib",
"drug_normalized": "Abemaciclib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 27,
"end_char": 38
}
] | [] | 1 | progress_note |
ONCORX-0002 | Per oncology, continue Pembrolizumab. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Pembrolizumab",
"drug_normalized": "Pembrolizumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 23,
"end_char": 36
}
] | [] | 1 | progress_note |
ONCORX-0003 | Recommend initiation of Chlorambucil. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Chlorambucil",
"drug_normalized": "Chlorambucil",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 24,
"end_char": 36
}
] | [] | 1 | treatment_plan |
ONCORX-0004 | Current therapy: Capecitabine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Capecitabine",
"drug_normalized": "Capecitabine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 17,
"end_char": 29
}
] | [] | 1 | treatment_plan |
ONCORX-0006 | Treatment: Niraparib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Niraparib",
"drug_normalized": "Niraparib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 11,
"end_char": 20
}
] | [] | 1 | progress_note |
ONCORX-0008 | Oncology recommends Carmustine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Carmustine",
"drug_normalized": "Carmustine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 20,
"end_char": 30
}
] | [] | 1 | treatment_plan |
ONCORX-0010 | Home medications include Leuprolide. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Leuprolide",
"drug_normalized": "Leuprolide",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 25,
"end_char": 35
}
] | [] | 1 | treatment_plan |
ONCORX-0011 | Treatment: Ixazomib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Ixazomib",
"drug_normalized": "Ixazomib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 11,
"end_char": 19
}
] | [] | 1 | progress_note |
ONCORX-0012 | Please continue Sunitinib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Sunitinib",
"drug_normalized": "Sunitinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 16,
"end_char": 25
}
] | [] | 1 | oncology_consult |
ONCORX-0013 | Currently maintained on Trastuzumab. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Trastuzumab",
"drug_normalized": "Trastuzumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 24,
"end_char": 35
}
] | [] | 1 | progress_note |
ONCORX-0014 | Initiate therapy with Durvalumab as discussed. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Durvalumab",
"drug_normalized": "Durvalumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 22,
"end_char": 32
}
] | [] | 1 | progress_note |
ONCORX-0015 | Treatment: Exemestane. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Exemestane",
"drug_normalized": "Exemestane",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 11,
"end_char": 21
}
] | [] | 1 | oncology_consult |
ONCORX-0016 | Recommend initiation of Mercaptopurine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Mercaptopurine",
"drug_normalized": "Mercaptopurine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 24,
"end_char": 38
}
] | [] | 1 | progress_note |
ONCORX-0017 | Assessment/Plan: Durvalumab for treatment. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Durvalumab",
"drug_normalized": "Durvalumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 17,
"end_char": 27
}
] | [] | 1 | progress_note |
ONCORX-0018 | Pt currently receiving Bendamustine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Bendamustine",
"drug_normalized": "Bendamustine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 23,
"end_char": 35
}
] | [] | 1 | progress_note |
ONCORX-0019 | Currently maintained on Gefitinib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Gefitinib",
"drug_normalized": "Gefitinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 24,
"end_char": 33
}
] | [] | 1 | oncology_consult |
ONCORX-0020 | Per oncology, continue Everolimus. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Everolimus",
"drug_normalized": "Everolimus",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 23,
"end_char": 33
}
] | [] | 1 | progress_note |
ONCORX-0021 | Medications: Degarelix. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Degarelix",
"drug_normalized": "Degarelix",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 13,
"end_char": 22
}
] | [] | 1 | treatment_plan |
ONCORX-0022 | The patient is scheduled to receive Cytarabine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Cytarabine",
"drug_normalized": "Cytarabine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 36,
"end_char": 46
}
] | [] | 1 | oncology_consult |
ONCORX-0024 | Home medications include Ramucirumab. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Ramucirumab",
"drug_normalized": "Ramucirumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 25,
"end_char": 36
}
] | [] | 1 | treatment_plan |
ONCORX-0025 | Currently maintained on Dexamethasone. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Dexamethasone",
"drug_normalized": "Dexamethasone",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 24,
"end_char": 37
}
] | [] | 1 | oncology_consult |
ONCORX-0027 | Continue Idarubicin as previously prescribed. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Idarubicin",
"drug_normalized": "Idarubicin",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 9,
"end_char": 19
}
] | [] | 1 | treatment_plan |
ONCORX-0028 | Resume Carmustine after hold period. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Carmustine",
"drug_normalized": "Carmustine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 7,
"end_char": 17
}
] | [] | 1 | oncology_consult |
ONCORX-0029 | Currently maintained on Ifosfamide. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Ifosfamide",
"drug_normalized": "Ifosfamide",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 24,
"end_char": 34
}
] | [] | 1 | progress_note |
ONCORX-0030 | The patient was started on Elotuzumab. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Elotuzumab",
"drug_normalized": "Elotuzumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 27,
"end_char": 37
}
] | [] | 1 | oncology_consult |
ONCORX-0031 | Medications: Mercaptopurine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Mercaptopurine",
"drug_normalized": "Mercaptopurine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 13,
"end_char": 27
}
] | [] | 1 | treatment_plan |
ONCORX-0032 | Patient seen in clinic today, currently on Ramucirumab. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Ramucirumab",
"drug_normalized": "Ramucirumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 43,
"end_char": 54
}
] | [] | 1 | progress_note |
ONCORX-0033 | Patient seen in clinic today, currently on Osimertinib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Osimertinib",
"drug_normalized": "Osimertinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 43,
"end_char": 54
}
] | [] | 1 | progress_note |
ONCORX-0034 | Per oncology, continue Darolutamide. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Darolutamide",
"drug_normalized": "Darolutamide",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 23,
"end_char": 35
}
] | [] | 1 | treatment_plan |
ONCORX-0035 | Current therapy: Pegfilgrastim. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Pegfilgrastim",
"drug_normalized": "Pegfilgrastim",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 17,
"end_char": 30
}
] | [] | 1 | treatment_plan |
ONCORX-0036 | Will proceed with Cyclophosphamide. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Cyclophosphamide",
"drug_normalized": "Cyclophosphamide",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 18,
"end_char": 34
}
] | [] | 1 | treatment_plan |
ONCORX-0038 | Dacarbazine was administered during today's visit. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Dacarbazine",
"drug_normalized": "Dacarbazine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 0,
"end_char": 11
}
] | [] | 1 | oncology_consult |
ONCORX-0039 | Per oncology, continue Crizotinib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Crizotinib",
"drug_normalized": "Crizotinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 23,
"end_char": 33
}
] | [] | 1 | treatment_plan |
ONCORX-0041 | Assessment/Plan: Letrozole for treatment. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Letrozole",
"drug_normalized": "Letrozole",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 17,
"end_char": 26
}
] | [] | 1 | progress_note |
ONCORX-0043 | Assessment/Plan: Trastuzumab for treatment. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Trastuzumab",
"drug_normalized": "Trastuzumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 17,
"end_char": 28
}
] | [] | 1 | oncology_consult |
ONCORX-0045 | Please continue Azacitidine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Azacitidine",
"drug_normalized": "Azacitidine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 16,
"end_char": 27
}
] | [] | 1 | treatment_plan |
ONCORX-0047 | Pt currently receiving Acalabrutinib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Acalabrutinib",
"drug_normalized": "Acalabrutinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 23,
"end_char": 36
}
] | [] | 1 | treatment_plan |
ONCORX-0048 | Recommend initiation of Pazopanib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Pazopanib",
"drug_normalized": "Pazopanib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 24,
"end_char": 33
}
] | [] | 1 | oncology_consult |
ONCORX-0049 | Patient reports taking Methotrexate at home. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Methotrexate",
"drug_normalized": "Methotrexate",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 23,
"end_char": 35
}
] | [] | 1 | treatment_plan |
ONCORX-0051 | Please continue Nivolumab. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Nivolumab",
"drug_normalized": "Nivolumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 16,
"end_char": 25
}
] | [] | 1 | oncology_consult |
ONCORX-0052 | Please continue Prednisone. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Prednisone",
"drug_normalized": "Prednisone",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 16,
"end_char": 26
}
] | [] | 1 | oncology_consult |
ONCORX-0053 | Patient reports taking Afatinib at home. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Afatinib",
"drug_normalized": "Afatinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 23,
"end_char": 31
}
] | [] | 1 | progress_note |
ONCORX-0054 | Venetoclax initiated per protocol. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Venetoclax",
"drug_normalized": "Venetoclax",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 0,
"end_char": 10
}
] | [] | 1 | progress_note |
ONCORX-0055 | Continue Atezolizumab as previously prescribed. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Atezolizumab",
"drug_normalized": "Atezolizumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 9,
"end_char": 21
}
] | [] | 1 | progress_note |
ONCORX-0056 | Home medications include Vinblastine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Vinblastine",
"drug_normalized": "Vinblastine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 25,
"end_char": 36
}
] | [] | 1 | progress_note |
ONCORX-0057 | Current therapy: Rituximab. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Rituximab",
"drug_normalized": "Rituximab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 17,
"end_char": 26
}
] | [] | 1 | oncology_consult |
ONCORX-0059 | Will proceed with Crizotinib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Crizotinib",
"drug_normalized": "Crizotinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 18,
"end_char": 28
}
] | [] | 1 | oncology_consult |
ONCORX-0060 | Per oncology, continue Bortezomib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Bortezomib",
"drug_normalized": "Bortezomib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 23,
"end_char": 33
}
] | [] | 1 | treatment_plan |
ONCORX-0062 | The patient was started on Goserelin. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Goserelin",
"drug_normalized": "Goserelin",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 27,
"end_char": 36
}
] | [] | 1 | treatment_plan |
ONCORX-0064 | Home medications include Avelumab. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Avelumab",
"drug_normalized": "Avelumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 25,
"end_char": 33
}
] | [] | 1 | oncology_consult |
ONCORX-0065 | Discussed starting Gemcitabine with the patient. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Gemcitabine",
"drug_normalized": "Gemcitabine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 19,
"end_char": 30
}
] | [] | 1 | oncology_consult |
ONCORX-0066 | Medications: Vinorelbine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Vinorelbine",
"drug_normalized": "Vinorelbine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 13,
"end_char": 24
}
] | [] | 1 | progress_note |
ONCORX-0068 | Oncology recommends Procarbazine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Procarbazine",
"drug_normalized": "Procarbazine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 20,
"end_char": 32
}
] | [] | 1 | progress_note |
ONCORX-0069 | The patient is scheduled to receive Zanubrutinib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Zanubrutinib",
"drug_normalized": "Zanubrutinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 36,
"end_char": 48
}
] | [] | 1 | progress_note |
ONCORX-0070 | Home medications include Brentuximab Vedotin. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Brentuximab Vedotin",
"drug_normalized": "Brentuximab Vedotin",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 25,
"end_char": 44
}
] | [] | 1 | oncology_consult |
ONCORX-0071 | Home medications include Cetuximab. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Cetuximab",
"drug_normalized": "Cetuximab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 25,
"end_char": 34
}
] | [] | 1 | treatment_plan |
ONCORX-0073 | Resume Osimertinib after hold period. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Osimertinib",
"drug_normalized": "Osimertinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 7,
"end_char": 18
}
] | [] | 1 | progress_note |
ONCORX-0074 | Resume Ixazomib after hold period. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Ixazomib",
"drug_normalized": "Ixazomib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 7,
"end_char": 15
}
] | [] | 1 | treatment_plan |
ONCORX-0076 | Dasatinib initiated per protocol. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Dasatinib",
"drug_normalized": "Dasatinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 0,
"end_char": 9
}
] | [] | 1 | progress_note |
ONCORX-0077 | The patient is scheduled to receive Gemcitabine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Gemcitabine",
"drug_normalized": "Gemcitabine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 36,
"end_char": 47
}
] | [] | 1 | oncology_consult |
ONCORX-0079 | Continue Lomustine as previously prescribed. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Lomustine",
"drug_normalized": "Lomustine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 9,
"end_char": 18
}
] | [] | 1 | progress_note |
ONCORX-0080 | Please continue Polatuzumab Vedotin. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Polatuzumab Vedotin",
"drug_normalized": "Polatuzumab Vedotin",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 16,
"end_char": 35
}
] | [] | 1 | progress_note |
ONCORX-0081 | Patient has been on Ifosfamide since last visit. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Ifosfamide",
"drug_normalized": "Ifosfamide",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 20,
"end_char": 30
}
] | [] | 1 | oncology_consult |
ONCORX-0083 | Recommend initiation of Avelumab. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Avelumab",
"drug_normalized": "Avelumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 24,
"end_char": 32
}
] | [] | 1 | progress_note |
ONCORX-0084 | Apalutamide initiated per protocol. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Apalutamide",
"drug_normalized": "Apalutamide",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 0,
"end_char": 11
}
] | [] | 1 | treatment_plan |
ONCORX-0085 | Per oncology, continue Etoposide. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Etoposide",
"drug_normalized": "Etoposide",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 23,
"end_char": 32
}
] | [] | 1 | treatment_plan |
ONCORX-0086 | Will proceed with Brentuximab Vedotin. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Brentuximab Vedotin",
"drug_normalized": "Brentuximab Vedotin",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 18,
"end_char": 37
}
] | [] | 1 | oncology_consult |
ONCORX-0087 | The patient is scheduled to receive Busulfan. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Busulfan",
"drug_normalized": "Busulfan",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 36,
"end_char": 44
}
] | [] | 1 | treatment_plan |
ONCORX-0088 | Patient has been on Atezolizumab since last visit. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Atezolizumab",
"drug_normalized": "Atezolizumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 20,
"end_char": 32
}
] | [] | 1 | treatment_plan |
ONCORX-0089 | Active medication: Mitomycin. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Mitomycin",
"drug_normalized": "Mitomycin",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 19,
"end_char": 28
}
] | [] | 1 | oncology_consult |
ONCORX-0090 | Current therapy: Lorlatinib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Lorlatinib",
"drug_normalized": "Lorlatinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 17,
"end_char": 27
}
] | [] | 1 | treatment_plan |
ONCORX-0091 | Medications: Osimertinib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Osimertinib",
"drug_normalized": "Osimertinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 13,
"end_char": 24
}
] | [] | 1 | treatment_plan |
ONCORX-0092 | The patient was started on Sunitinib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Sunitinib",
"drug_normalized": "Sunitinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 27,
"end_char": 36
}
] | [] | 1 | progress_note |
ONCORX-0094 | Please continue Oxaliplatin. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Oxaliplatin",
"drug_normalized": "Oxaliplatin",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 16,
"end_char": 27
}
] | [] | 1 | treatment_plan |
ONCORX-0095 | Please continue Carmustine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Carmustine",
"drug_normalized": "Carmustine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 16,
"end_char": 26
}
] | [] | 1 | progress_note |
ONCORX-0097 | Continue Ribociclib as previously prescribed. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Ribociclib",
"drug_normalized": "Ribociclib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 9,
"end_char": 19
}
] | [] | 1 | progress_note |
ONCORX-0099 | Assessment/Plan: Elotuzumab for treatment. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Elotuzumab",
"drug_normalized": "Elotuzumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 17,
"end_char": 27
}
] | [] | 1 | progress_note |
ONCORX-0100 | Patient reports taking Venetoclax at home. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Venetoclax",
"drug_normalized": "Venetoclax",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 23,
"end_char": 33
}
] | [] | 1 | oncology_consult |
ONCORX-0101 | Darolutamide initiated per protocol. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Darolutamide",
"drug_normalized": "Darolutamide",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 0,
"end_char": 12
}
] | [] | 1 | progress_note |
ONCORX-0102 | Recommend initiation of Ixazomib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Ixazomib",
"drug_normalized": "Ixazomib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 24,
"end_char": 32
}
] | [] | 1 | treatment_plan |
ONCORX-0104 | Olaparib initiated per protocol. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Olaparib",
"drug_normalized": "Olaparib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 0,
"end_char": 8
}
] | [] | 1 | progress_note |
ONCORX-0105 | Cemiplimab initiated per protocol. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Cemiplimab",
"drug_normalized": "Cemiplimab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 0,
"end_char": 10
}
] | [] | 1 | oncology_consult |
ONCORX-0106 | The patient was started on Bleomycin. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Bleomycin",
"drug_normalized": "Bleomycin",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 27,
"end_char": 36
}
] | [] | 1 | progress_note |
ONCORX-0107 | Treatment: Apalutamide. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Apalutamide",
"drug_normalized": "Apalutamide",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 11,
"end_char": 22
}
] | [] | 1 | oncology_consult |
ONCORX-0108 | Treatment: Trametinib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Trametinib",
"drug_normalized": "Trametinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 11,
"end_char": 21
}
] | [] | 1 | oncology_consult |
ONCORX-0109 | Patient has been on Elotuzumab since last visit. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Elotuzumab",
"drug_normalized": "Elotuzumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 20,
"end_char": 30
}
] | [] | 1 | progress_note |
ONCORX-0110 | Home medications include Tamoxifen. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Tamoxifen",
"drug_normalized": "Tamoxifen",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 25,
"end_char": 34
}
] | [] | 1 | treatment_plan |
ONCORX-0111 | Continue Fluorouracil as previously prescribed. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Fluorouracil",
"drug_normalized": "Fluorouracil",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 9,
"end_char": 21
}
] | [] | 1 | oncology_consult |
ONCORX-0112 | Assessment/Plan: Degarelix for treatment. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Degarelix",
"drug_normalized": "Degarelix",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 17,
"end_char": 26
}
] | [] | 1 | progress_note |
ONCORX-0114 | Medications: Carfilzomib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Carfilzomib",
"drug_normalized": "Carfilzomib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 13,
"end_char": 24
}
] | [] | 1 | progress_note |
ONCORX-0115 | Trametinib was administered during today's visit. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Trametinib",
"drug_normalized": "Trametinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 0,
"end_char": 10
}
] | [] | 1 | oncology_consult |
ONCORX-0116 | Patient reports taking Axitinib at home. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Axitinib",
"drug_normalized": "Axitinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 23,
"end_char": 31
}
] | [] | 1 | progress_note |
ONCORX-0117 | Initiate therapy with Sorafenib as discussed. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Sorafenib",
"drug_normalized": "Sorafenib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 22,
"end_char": 31
}
] | [] | 1 | treatment_plan |
ONCORX-0119 | The patient is scheduled to receive Bendamustine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Bendamustine",
"drug_normalized": "Bendamustine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 36,
"end_char": 48
}
] | [] | 1 | progress_note |
ONCORX-0120 | Treatment: Etoposide. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Etoposide",
"drug_normalized": "Etoposide",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 11,
"end_char": 20
}
] | [] | 1 | oncology_consult |
ONCORX-0122 | Continue Methylprednisolone as previously prescribed. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Methylprednisolone",
"drug_normalized": "Methylprednisolone",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 9,
"end_char": 27
}
] | [] | 1 | progress_note |
ONCORX-0124 | The patient is scheduled to receive Procarbazine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Procarbazine",
"drug_normalized": "Procarbazine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 36,
"end_char": 48
}
] | [] | 1 | oncology_consult |
ONCORX-0125 | Treatment: Thioguanine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Thioguanine",
"drug_normalized": "Thioguanine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 11,
"end_char": 22
}
] | [] | 1 | treatment_plan |
ONCORX-0126 | Initiate therapy with Degarelix as discussed. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Degarelix",
"drug_normalized": "Degarelix",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 22,
"end_char": 31
}
] | [] | 1 | treatment_plan |
ONCORX-0127 | Active medication: Apalutamide. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Apalutamide",
"drug_normalized": "Apalutamide",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 19,
"end_char": 30
}
] | [] | 1 | oncology_consult |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.